Limited efficacy of daratumumab in multiple myeloma with extramedullary disease
Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
34247197
DOI
10.1038/s41375-021-01343-w
PII: 10.1038/s41375-021-01343-w
Knihovny.cz E-zdroje
- MeSH
- antitumorózní látky terapeutické užití MeSH
- buněčné klony účinky léků patologie MeSH
- lidé MeSH
- míra přežití MeSH
- mnohočetný myelom farmakoterapie patologie MeSH
- monoklonální protilátky terapeutické užití MeSH
- následné studie MeSH
- plazmatické buňky účinky léků patologie MeSH
- prognóza MeSH
- retrospektivní studie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- antitumorózní látky MeSH
- daratumumab MeSH Prohlížeč
- monoklonální protilátky MeSH
Department of Biology and Ecology Faculty of Science University of Ostrava Ostrava Czech Republic
Department of Clinical Hematology University Hospital Brno Brno Czech Republic
Department of Nuclear Medicine University Hospital Ostrava Ostrava Czech Republic
Department of Pathology University Hospital Ostrava Ostrava Czech Republic
Hematology and Oncology Department Charles University Hospital Pilsen Czechia Czech Republic
Institute of Biostatistics and Analyses Ltd Brno Czech Republic
Zobrazit více v PubMed
Dimopoulos MA, Moreau P, Terpos E, Mateos M-V, Zweegman S, Cook G, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Hemasphere. 2021;5:e528. PubMed PMC
Bhutani M, Foureau DM, Atrash S, Voorhees PM, Usmani SZ. Extramedullary multiple myeloma. Leukemia. 2020;34:1–20. PubMed DOI
Sevcikova S, Minarik J, Stork M, Jelinek T, Pour L, Hajek R. Extramedullary disease in multiple myeloma—controversies and future directions. Blood Rev. 2019;36:32–39. PubMed DOI
Pour L, Sevcikova S, Greslikova H, Kupska R, Majkova P, Zahradova L, et al. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica. 2014;99:360–4. PubMed DOI PMC
Gagelmann N, Eikema D-J, Iacobelli S, Koster L, Nahi H, Stoppa A-M, et al. Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT. Haematologica. 2018;103:890–7. PubMed DOI PMC
van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397:410–27. PubMed DOI
Jelinek T, Hajek R. Monoclonal antibodies—A new era in the treatment of multiple myeloma. Blood Rev. 2016;30:101–10. PubMed DOI
Nijhof IS, Casneuf T, van Velzen J, van Kessel B, Axel AE, Syed K, et al. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood. 2016;128:959–70. PubMed DOI
Moreno L, Perez C, Zabaleta A, Manrique I, Alignani D, Ajona D, et al. The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma. Clinical Cancer Res. 2019;25:3176–87. DOI
Choudhry P, Mariano MC, Geng H, Martin TG, Wolf JL, Wong SW, et al. DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma. Leukemia. 2020;34:938–41. PubMed DOI
Emran AA, Chatterjee A, Rodger EJ, Tiffen JC, Gallagher SJ, Eccles MR, et al. Targeting DNA methylation and EZH2 activity to overcome melanoma resistance to immunotherapy. Trends Immunol. 2019;40:328–44. PubMed DOI
Varlet E, Ovejero S, Martinez A-M, Cavalli G, Moreaux J. Role of polycomb complexes in normal and malignant plasma cells. Int J Mol Sci. 2020;21:8047. DOI PMC
Piedra-Quintero Z. L., Wilson Z., Nava P., Guerau-de-Arellano M. CD38: an immunomodulatory molecule in inflammation and autoimmunity. Front Immunol. 2020; 11. https://doi.org/10.3389/fimmu.2020.597959 .
Beksac M. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma and soft-tissue plasmacytomas: Icaria-MM Subgroup Analysis. ASH, 2020 https://ash.confex.com/ash/2020/webprogram/Paper134727.html (accessed 11 Mar2021).
Bahlis NJ, Dimopoulos MA, White DJ, Benboubker L, Cook G, Leiba M, et al. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia. 2020;34:1875–84. PubMed DOI PMC
Real-World Evidence on Prognostic Value of MRD in Multiple Myeloma Using Flow Cytometry
More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma
Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas
Identification of patients at high risk of secondary extramedullary multiple myeloma development
Natural Killer Cells in the Malignant Niche of Multiple Myeloma
